STAT3, CPTAC-1275 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
Protein Sequence hover to view complete sequence
CPTAC-5962: View additional TGVQFTTK data
CPTAC-1275: View additional FPELNYQLK data
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MAQWNQLQQL | DTRYLEQLHQ | LYSDSFPMEL | RQFLAPWIES | QDWAYAASKE |
| 60 | 70 | 80 | 90 | 100 |
| SHATLVFHNL | LGEIDQQYSR | FLQESNVLYQ | HNLRRIKQFL | QSRYLEKPME |
| 110 | 120 | 130 | 140 | 150 |
| IARIVARCLW | EESRLLQTAA | TAAQQGGQAN | HPTAAVVTEK | QQMLEQHLQD |
| 160 | 170 | 180 | 190 | 200 |
| VRKRVQDLEQ | KMKVVENLQD | DFDFNYKTLK | SQGDMQDLNG | NNQSVTRQKM |
| 210 | 220 | 230 | 240 | 250 |
| QQLEQMLTAL | DQMRRSIVSE | LAGLLSAMEY | VQKTLTDEEL | ADWKRRQQIA |
| 260 | 270 | 280 | 290 | 300 |
| CIGGPPNICL | DRLENWITSL | AESQLQTRQQ | IKKLEELQQK | VSYKGDPIVQ |
| 310 | 320 | 330 | 340 | 350 |
| HRPMLEERIV | ELFRNLMKSA | FVVERQPCMP | MHPDRPLVIK | TGVQFTTKVR |
| 360 | 370 | 380 | 390 | 400 |
| LLVKFPELNY | QLKIKVCIDK | DSGDVAALRG | SRKFNILGTN | TKVMNMEESN |
| 410 | 420 | 430 | 440 | 450 |
| NGSLSAEFKH | LTLREQRCGN | GGRANCDASL | IVTEELHLIT | FETEVYHQGL |
| 460 | 470 | 480 | 490 | 500 |
| KIDLETHSLP | VVVISNICQM | PNAWASILWY | NMLTNNPKNV | NFFTKPPIGT |
| 510 | 520 | 530 | 540 | 550 |
| WDQVAEVLSW | QFSSTTKRGL | SIEQLTTLAE | KLLGPGVNYS | GCQITWAKFC |
| 560 | 570 | 580 | 590 | 600 |
| KENMAGKGFS | FWVWLDNIID | LVKKYILALW | NEGYIMGFIS | KERERAILST |
| 610 | 620 | 630 | 640 | 650 |
| KPPGTFLLRF | SESSKEGGVT | FTWVEKDISG | KTQIQSVEPY | TKQQLNNMSF |
| 660 | 670 | 680 | 690 | 700 |
| AEIIMGYKIM | DATNILVSPL | VYLYPDIPKE | EAFGKYCRPE | SQEHPEADPG |
| 710 | 720 | 730 | 740 | 750 |
| SAAPYLKTKF | ICVTPTTCSN | TIDLPMSPRT | LDSLMQFGNN | GEGAEPSAGG |
| 760 | 770 | |||
| QFESLTFDME | LTSECATSPM |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for non-CPTAC-6251 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
YC[+57.021464]RPESQEHPEADPGSAAPY[+79.966331]LK
Modification Type
Carbamidomethyl (C)
Protein - Site of Modification
N/A
Peptide - Site of Modification
8
Peptide Start
686
Peptide End
707
CPTAC ID
non-CPTAC-6251
Peptide Molecular Mass
2,581.0945
Species
Human
Assay Type
Enrichment MRM or SRM
Enrichment Method
N/A
Matrix
SKBR3 cells
Submitting Laboratory
Cell Signaling Technology
Submitting Lab PI
Yiying Zhu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
Orbitrap Q Exactive (Thermo)
Internal Standard
Heavy isotope-labeled peptides
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N
LC
EASY-nLC II (Thermo)
Column Packing
self-packed
Column Dimensions
ID 100um, length 15cm
Flow Rate
300 nL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y4 (1+) | 5.6 | 6.8 | 10.5 | 9.5 | 6.7 | 12.7 | 11 | 9.5 | 16.5 | 15 | 15 | 15 |
| y13 (2+) | 15.6 | 6.7 | 10.8 | 16.2 | 5.6 | 14.3 | 22.5 | 8.7 | 17.9 | 15 | 15 | 15 |
| b9 (2+) | 10.1 | 7.1 | 10.8 | 13.6 | 6.2 | 12.8 | 16.9 | 9.4 | 16.7 | 15 | 15 | 15 |
| sum | 5.7 | 6.7 | 10.5 | 8.1 | 6.2 | 12.9 | 9.9 | 9.1 | 16.6 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for CPTAC-5962 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Sequence
TGVQFTTK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
4
Peptide Start
341
Peptide End
348
CPTAC ID
CPTAC-5962
Peptide Molecular Mass
880.4654
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM or SRM
Enrichment Method
N/A
Matrix
FFPE tumor tissue lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich
Publication
View Details (opens in a new window)
Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.Whiteaker JR, Lundeen RA, Zhao L, Schoenherr RM, Burian A, Huang D, Voytovich U, Wang T, Kennedy JJ, Ivey RG, Lin C, Murillo OD, Lorentzen TD, Thiagarajan M, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Reading JJ, Kaczmarczyk JA, Richardson CW, Garcia-Buntley SS, Bocik W, Hewitt SM, Murray KE, Do N, Brophy M, Wilz SW, Yu H, Ajjarapu S, Boja E, Hiltke T, Rodriguez H, Paulovich AG.Front Immunol. 2021 Nov 11;12:765898. doi: 10.3389/fimmu.2021.765898. eCollection 2021.PMID: 34858420
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
QTRAP 5500
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent nanoLC 425
Column Packing
3 µm ChromXP C18EP, 120 Å
Column Dimensions
150 x 0.3 mm
Flow Rate
0.3 µL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y3 (1+) | 15.1 | 15.9 | 8.1 | 21.9 | 21.2 | 12.5 | 26.6 | 26.5 | 14.9 | 13 | 25 | 14 |
| b6 (1+) | 26.9 | 23.1 | 18.1 | 33.2 | 23.5 | 20.4 | 42.7 | 33 | 27.3 | 13 | 25 | 14 |
| b5 (1+) | 16.3 | 17.6 | 13.7 | 18.8 | 19.2 | 14.3 | 24.9 | 26 | 19.8 | 13 | 25 | 14 |
| b4 (1+) | 13.5 | 17.3 | 8.4 | 15.5 | 20.9 | 13.3 | 20.6 | 27.1 | 15.7 | 13 | 25 | 14 |
| b3 (1+) | 17.3 | 5.6 | 6 | 14.5 | 14.1 | 10.8 | 22.6 | 15.2 | 12.4 | 13 | 25 | 14 |
| y4 (1+) | 5.3 | 5.5 | 4.7 | 7.4 | 11.5 | 7.6 | 9.1 | 12.7 | 8.9 | 13 | 25 | 14 |
| y5 (1+) | 10.3 | 6.7 | 5.6 | 11.8 | 13.9 | 11.7 | 15.7 | 15.4 | 13 | 13 | 25 | 14 |
| y6 (1+) | 8.9 | 7.8 | 5.2 | 7.9 | 16 | 12 | 11.9 | 17.8 | 13.1 | 13 | 25 | 14 |
| sum | 8.1 | 3.8 | 4.2 | 10 | 13.2 | 10 | 12.9 | 13.7 | 10.8 | 13 | 25 | 14 |
Additional Resources and Comments
Assay Details for non-CPTAC-5440 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
FIC[+57.021464]VTPTTC[+57.021464]SNTIDLPMSPR
Modification Type
Carbamidomethyl (C), Carbamidomethyl (C)
Protein - Site of Modification
713, 719
Peptide - Site of Modification
3, 9
Peptide Start
710
Peptide End
729
CPTAC ID
non-CPTAC-5440
Peptide Molecular Mass
2,309.0854
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Cell Lysate
Submitting Laboratory
Moffitt Cancer Center
Submitting Lab PI
John Koomen
Publication
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
RSLCnano and Quantiva
Internal Standard
Stable Isotope Labeled Standard
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
RSLCnano
Column Packing
C18 PepMap 100
Column Dimensions
75 micron ID x 25 cm length
Flow Rate
300 nl/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| b3 (1+) | 9.2 | 4.2 | 3.6 | 10.7 | 4.4 | 4.4 | 14.1 | 6.1 | 5.7 | 15 | 15 | 15 |
| y5 (1+) | 7 | 2.7 | 3.1 | 6.4 | 4.2 | 4.3 | 9.5 | 5 | 5.3 | 15 | 15 | 15 |
| y6 (1+) | 7.9 | 4.8 | 4.1 | 8.1 | 4.7 | 5.9 | 11.3 | 6.7 | 7.2 | 15 | 15 | 15 |
| sum | 3.8 | 2.1 | 2.9 | 4.2 | 3.3 | 4.3 | 5.7 | 3.9 | 5.2 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for non-CPTAC-5713 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
FIC[+57.021464]VTPTTC[+57.021464]SNTIDLPMS[+79.966331]PR
Modification Type
Phospho (ST)
Protein - Site of Modification
N/A
Peptide - Site of Modification
3
Peptide Start
710
Peptide End
729
CPTAC ID
non-CPTAC-5713
Peptide Molecular Mass
2,389.0517
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM or SRM
Enrichment Method
N/A
Matrix
Cell Lysate
Submitting Laboratory
Moffitt Cancer Center
Submitting Lab PI
John Koomen
Publication
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
Thermo Quantiva
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Dionex Ultimate 3000 RSLCnano
Column Packing
Pepmap 100
Column Dimensions
75um x 25cm
Flow Rate
300 nL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y6-98 (1+) | 28.2 | 9.8 | 7.6 | 38.8 | 13.2 | 5.9 | 48 | 16.4 | 9.6 | 15 | 15 | 15 |
| y5 (1+) | 8.3 | 7.1 | 5.3 | 10.4 | 13.8 | 7.9 | 13.3 | 15.5 | 9.5 | 15 | 15 | 15 |
| y5-98 (1+) | 12.6 | 7.4 | 7.3 | 19.8 | 11.9 | 7.4 | 23.5 | 14 | 10.4 | 15 | 15 | 15 |
| b3 (1+) | 20.1 | 4.7 | 5.2 | 22.8 | 9.3 | 7.1 | 30.4 | 10.4 | 8.8 | 15 | 15 | 15 |
| sum | 9 | 4.5 | 4.8 | 11.6 | 10.2 | 5.8 | 14.7 | 11.1 | 7.5 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for non-CPTAC-5439 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
YC[+57.021464]RPESQEHPEADPGSAAPYLK
Modification Type
Carbamidomethyl (C)
Protein - Site of Modification
688
Peptide - Site of Modification
2
Peptide Start
686
Peptide End
707
CPTAC ID
non-CPTAC-5439
Peptide Molecular Mass
2,501.1281
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Cell Lysate
Submitting Laboratory
Moffitt Cancer Center
Submitting Lab PI
John Koomen
Publication
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
RSLCnano and Quantiva
Internal Standard
Stable Isotope Labeled Standard
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N
LC
RSLCnano
Column Packing
C18 PepMap 100
Column Dimensions
75 micron ID x 25 cm length
Flow Rate
300 nl/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y9 (2+) | 12.4 | 5 | 4 | 10.6 | 4.8 | 6 | 16.3 | 6.9 | 7.2 | 15 | 15 | 15 |
| y4 (1+) | 6.4 | 2.1 | 2 | 7.3 | 2.9 | 3.8 | 9.7 | 3.6 | 4.3 | 15 | 15 | 15 |
| b13 (2+) | 4.8 | 1.9 | 3.1 | 6.7 | 2.3 | 3.1 | 8.2 | 3 | 4.4 | 15 | 15 | 15 |
| b9 (1+) | 14.1 | 6.5 | 3.3 | 13.3 | 6.8 | 5.2 | 19.4 | 9.4 | 6.2 | 15 | 15 | 15 |
| b8 (1+) | 13.9 | 2.4 | 4.9 | 11.1 | 4.2 | 4.5 | 17.8 | 4.8 | 6.7 | 15 | 15 | 15 |
| sum | 3.9 | 1.3 | 2 | 5.1 | 1.7 | 3.1 | 6.4 | 2.1 | 3.7 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for non-CPTAC-5714 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
YC[+57.021464]RPESQEHPEADPGSAAPY[+79.966331]LK
Modification Type
Phospho (Y)
Protein - Site of Modification
N/A
Peptide - Site of Modification
3
Peptide Start
686
Peptide End
707
CPTAC ID
non-CPTAC-5714
Peptide Molecular Mass
2,581.0945
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM or SRM
Enrichment Method
N/A
Matrix
Cell Lysate
Submitting Laboratory
Moffitt Cancer Center
Submitting Lab PI
John Koomen
Publication
View Details (opens in a new window)
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Cell Reports Methods doi: 10.1016/j.crmeth.2021.100015.
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
Thermo Quantiva
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N
LC
Dionex Ultimate 3000 RSLCnano
Column Packing
Pepmap 100
Column Dimensions
75um x 25cm
Flow Rate
300 nL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y4 (1+) | 2.2 | 2 | 1.2 | 2.7 | 1.4 | 1.6 | 3.5 | 2.4 | 2 | 15 | 15 | 15 |
| b9 (1+) | 5.5 | 3.2 | 2.3 | 4.5 | 3.3 | 3.1 | 7.1 | 4.6 | 3.9 | 15 | 15 | 15 |
| b13 (2+) | 2.6 | 3.2 | 0.9 | 4 | 3.5 | 3 | 4.8 | 4.7 | 3.1 | 15 | 15 | 15 |
| b9 (2+) | 5.3 | 2.9 | 2.4 | 7 | 3.5 | 2.4 | 8.8 | 4.5 | 3.4 | 15 | 15 | 15 |
| sum | 1.5 | 1.3 | 1 | 2.7 | 1.5 | 2.1 | 3.1 | 2 | 2.3 | 15 | 15 | 15 |
Additional Resources and Comments
Assay Details for CPTAC-1275 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Sequence
FPELNYQLK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
355
Peptide End
363
CPTAC ID
CPTAC-1275
Peptide Molecular Mass
1,150.6023
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 20.6 | 9.3 | 7.6 | 19.6 | 10.8 | 9 | 28.4 | 14.3 | 11.8 | 15 | 15 | 15 |
| y6 (1+) | 19.1 | 6.7 | 6.1 | 18.3 | 9.9 | 9.1 | 26.5 | 12 | 11 | 15 | 15 | 15 |
| y7 (1+) | 15.6 | 5.3 | 6.9 | 18.7 | 8 | 10.6 | 24.4 | 9.6 | 12.6 | 15 | 15 | 15 |
| sum | 11.9 | 5.8 | 5.6 | 11.7 | 8.5 | 8.8 | 16.7 | 10.3 | 10.4 | 15 | 15 | 15 |
Selectivity
Data source: Panorama
| Slope of Curve Fit for cell line | ||||||
|---|---|---|---|---|---|---|
| fragment_ion | 1 | 2 | 3 | 4 | 5 | 6 |
| y7 (1+) | 0.81 | 0.92 | 0.79 | 0.78 | 0.91 | 0.87 |
| y5 (1+) | 0.8 | 0.84 | 0.91 | 0.76 | 0.9 | 0.84 |
| y6 (1+) | 0.84 | 0.84 | 0.89 | 0.74 | 0.92 | 0.87 |
| sum | 0.82 | 0.87 | 0.86 | 0.76 | 0.91 | 0.87 |
Stability
Data source: Panorama
| Fragment ion / Transition | control_intra_CV | actual_temp_intra_CV | frozen_intra_CV | FTx1_intra_CV | FTx2_intra_CV |
|---|---|---|---|---|---|
| y5 (1+) | 10.1 | 3.4 | 0.7 | 7.6 | 1.9 |
| y7 (1+) | 5.3 | 2.4 | 4.7 | 2.3 | 2.4 |
| y6 (1+) | 6.5 | 5.7 | 3 | 4.7 | 2 |
| sum | 6.4 | 2.2 | 3.2 | 2.7 | 0.5 |
| Fragment ion / Transition | all_intra_CV | all_inter_CV |
|---|---|---|
| y5 (1+) | 4.5 | 4.9 |
| y7 (1+) | 3.2 | 4.3 |
| y6 (1+) | 4.6 | 4.5 |
| sum | 2.8 | 2.9 |
Endogenous
Data source: Panorama
| Fragment ion / Transition | intra_CV | inter_CV | total_CV |
|---|---|---|---|
| y6 (1+) | 43.3 | 53.3 | 68.7 |
| y7 (1+) | 41.5 | 58.9 | 72.1 |
| y5 (1+) | 40.9 | 58.4 | 71.3 |
| sum | 30.7 | 48.8 | 57.7 |
Additional Resources and Comments
Assay Details for CPTAC-1276 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Sequence
GLSIEQLTTLAEK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
519
Peptide End
531
CPTAC ID
CPTAC-1276
Peptide Molecular Mass
1,401.7715
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y8 (2+) | 70.1 | 33.3 | 51.6 | 105.1 | 39.9 | 72.1 | 126.3 | 52 | 88.7 | 15 | 15 | 15 |
| y9 (2+) | 48.3 | 22.7 | 17.4 | 63.3 | 27.5 | 27 | 79.6 | 35.7 | 32.1 | 15 | 15 | 15 |
| y9 (1+) | 6.2 | 10 | 13.1 | 27.9 | 16.6 | 16.3 | 28.6 | 19.4 | 20.9 | 15 | 15 | 15 |
| sum | 7.1 | 10 | 13 | 25.9 | 16.1 | 16.3 | 26.9 | 19 | 20.8 | 15 | 15 | 15 |
Selectivity
Data source: Panorama
| Slope of Curve Fit for cell line | ||||||
|---|---|---|---|---|---|---|
| fragment_ion | 1 | 2 | 3 | 4 | 5 | 6 |
| y8 (2+) | 1.94 | 4.74 | 2.91 | 0.35 | 1.69 | 1.2 |
| y9 (1+) | 6.37 | 7.42 | 4.45 | 5.47 | 11.67 | 5.1 |
| y9 (2+) | 4.6 | 8.92 | 4.78 | 4.32 | 8.29 | 4.49 |
| sum | 6.03 | 7.41 | 4.42 | 5.33 | 10.58 | 4.9 |
Stability
Data source: Panorama
| Fragment ion / Transition | control_intra_CV | actual_temp_intra_CV | frozen_intra_CV | FTx1_intra_CV | FTx2_intra_CV |
|---|
| Fragment ion / Transition | all_intra_CV | all_inter_CV |
|---|
Endogenous
Data source: Panorama
| Fragment ion / Transition | intra_CV | inter_CV | total_CV |
|---|---|---|---|
| y9 (1+) | 50.5 | 61.5 | 79.6 |
| y8 (2+) | 88.6 | 92.1 | 127.8 |
| y9 (2+) | 58.6 | 66.7 | 88.8 |
| sum | 51.6 | 62.4 | 81 |
Additional Resources and Comments
Assay Details for CPTAC-1751 Collapse assay details
Data source: Panorama
Official Gene Symbol
STAT3
Peptide Modified Sequence
YC[+57.0]RPESQEHPEADPGSAAPY[+80.0]LK
Modification Type
Carbamidomethyl (C), Phospho (Y)
Protein - Site of Modification
687, 705
Peptide - Site of Modification
2, 20
Peptide Start
686
Peptide End
707
CPTAC ID
CPTAC-1751
Peptide Molecular Mass
2,581.0945
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM or SRM
Enrichment Method
N/A
Matrix
Ovarian cancer cell lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| b13 (2+) | 24.7 | 9.1 | 10.2 | 26.1 | 13.1 | 12.3 | 35.9 | 16 | 16 | 15 | 15 | 15 |
| b8 (1+) | 11.7 | 11.7 | 11.8 | 11.3 | 7.8 | 13.1 | 16.3 | 14.1 | 17.6 | 15 | 15 | 15 |
| b9 (1+) | 15.6 | 7.7 | 10.6 | 16.3 | 10 | 9.8 | 22.6 | 12.6 | 14.4 | 15 | 15 | 15 |
| sum | 12.4 | 4.9 | 6.1 | 11.1 | 7.8 | 6.7 | 16.6 | 9.2 | 9.1 | 15 | 15 | 15 |